Fundz

Lantheus Holdings

Bedford, Massachusetts, United States · Biotechnology, Health Care, Therapeutics

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.

Key facts

Headquarters
Bedford, Massachusetts, United States
Employees
808
Industries
Biotechnology, Health Care, Therapeutics
Status
Public (LNTH)
Website
lantheus.com
LinkedIn
Company page

Recent activity at Lantheus Holdings

  • : SEC 8-K (8.01):
  • : SEC 8-K (8.01):
  • : SEC 8-K (8.01):
  • : SEC 8-K (5.02): On August 1, 2026, the Company amended its severance letter agreements with named executive officers, including Mary Anne Heino, Dr. Ludger Dinkelborg, Robert J. Marshall, Jr., Amanda Morgan, and Daniel M. Niedzwiecki. These amendments clarify that Converted PSU Awards will be subject to time-vesting only, and eligible executives may receive earned but unpaid bonuses in case of a Qualifying Termination following the merger's closing. Additionally, a $6.0 million transaction bonus pool was approved for select employees, with $4.0 million allocated to Mary Anne Heino and $500,000 to Daniel M. Niedzwiecki, contingent on their continued employment through the merger's effective time.
  • : SEC 8-K (8.01):
  • : SEC 8-K (7.01): On August 3, 2026, Lantheus Holdings, Inc. announced the execution of an Agreement and Plan of Merger with Curium US Holdings LLC and Coco Merger Sub Inc. This strategic merger agreement involves a joint effort between Lantheus, a publicly traded company, and Curium, which is aiming to strengthen their market position in the medical technology sector. The merger is designed to enhance product offerings and expand market reach. An investor presentation concerning the merger was also published on the same date, providing further details about the expected impacts and benefits of the merger for shareholders.
  • : SEC 8-K (5.02): On April 30, 2026, shareholders of Lantheus Holdings, Inc. approved the Amended and Restated 2026 Equity Incentive Plan, which increases the shares reserved for issuance by 2,000,000 and modifies the compensation structure for non-employee directors. This plan allows directors to receive a total of no more than $1,250,000 in combined cash and equity awards during their appointment year, and $750,000 in subsequent years. Additionally, a Certificate of Amendment was filed on the same day to declassify the Board of Directors over three years, enabling shareholders to remove directors with or without cause. These changes are strategic for aligning director incentives with shareholder interests and enhancing governance practices.
  • : Lantheus acquires Evergreen Theragnostics
  • : SEC 8-K (5.02): On November 6, 2025, Lantheus Holdings, Inc. announced the retirement of Chief Executive Officer Brian Markison, alongside the execution of a Consulting Agreement. Effective January 1, 2026, Mr. Markison will serve as an advisor to the Company through March 31, 2026, with an advisory fee of $83,333 per month, contingent upon compliance with restrictive covenants. In conjunction, the Retirement Agreement stipulates that Mr. Markison will continue to receive his base salary until December 31, 2025, and within 60 days thereafter, he is to receive a lump sum payment equal to his annual cash bonus for 2025 based on actual performance. The agreements include conditions related to the vesting of his outstanding equity awards, which will continue until the Retirement Date.
  • : SEC 8-K (5.02): On November 6, 2025, the Company reported that Brian Markison, the CEO and board member, will retire effective December 31, 2025, after notifying the Board on November 2, 2025. His retirement is not due to any disagreements regarding the Company. Concurrently, Mary Anne Heino has been appointed as Executive Chair effective November 7, 2025, and will act as the principal executive officer. Additionally, she will serve as Interim CEO starting January 1, 2026, earning a base salary of $83,333 per month, with a potential bonus of up to 110% of her base salary for fiscal 2026. Paul Blanchfield, the President, will also depart the Company on November 7, 2025, and Amanda Morgan will return to her position as Chief Commercial Officer.

Leadership

  • Jamie Spaeth, Chief People Officer
  • Jean -Claude Provost, Chief Science Officer
  • Amanda Morgan, Chief Commercial Officer

Verified email and direct lines for Lantheus Holdings’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Lantheus Holdings in the news

Companies similar to Lantheus Holdings

About Lantheus Holdings: questions and answers

What does Lantheus Holdings do?

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.

Where is Lantheus Holdings headquartered?

Lantheus Holdings is headquartered in Bedford, Massachusetts, United States.

How many employees does Lantheus Holdings have?

Lantheus Holdings has about 808 employees.

What is the latest news on Lantheus Holdings?

On Oct 21, 2026, SEC 8-K (8.01):

Is Lantheus Holdings a public company?

Yes. Lantheus Holdings is publicly traded under the ticker LNTH.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Lantheus Holdings across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.